Pfizer has stopped the distribution of the smoking cessation drug Chantix, and has recalled some batches after discovering high levels of a cancer-causing chemical called N-nitroso-varenicline (NDMA).

NDMA is considered a human carcinogen and has been linked with the development of various types of cancer, including breast cancer, bladder cancer, stomach cancer, testicular cancer and various other forms of cancer. High levels of NDMA have also been linked with liver damage.

Chantix (varenicline) was approved by the U.S. Food and Drug Administration (FDA) in 2006 as a medical aid used to overcome a nicotine addiction. It was designed to block receptors stimulated by nicotine, thereby reducing the craving to smoke. Shortly after its release, the FDA required Pfizer to add a “black box” warning, following a number of reports involving suicide and other unusual behavior among users. This warning was removed in 2016.

Our law firm is currently reviewing claims by current and former Chantix users who have been diagnosed with cancer or have suffered from liver damage.